Tag: CARTaGENE

Upcoming Webinar – CanPath’s Genomic Landscape

Posted on by pathwp

Webinar: CanPath’s genomic data landscape: Insights from Ontario and Quebec Canada’s largest genomic data resource just got bigger … how will you use it? ?? CanPath now offers even more genotyping data from the Ontario Health Study (OHS) and CARTaGENE (Quebec), creating new opportunities to explore genetic ancestry, disease risk, and innovative research approaches. Join Dr. Philip Awadalla and Dr. Guillaume Lettre on Tuesday, March 2, at 11:00 AM EDT as they describe: Ontario’s latest genotyping data & research applications Genetic ancestry, the French Canadian founder effect & whole genome sequencing Emerging tools like liquid biopsy, cell-free DNA & single-cell studies Registration: https://bit.ly/41mOPq1

Upcoming CanPath Webinar on Ultra-processed food consumption, depression, and diabetes

Posted on by pathwp

Type 2 diabetes (T2D) is a widespread chronic condition with severe consequences, including complications affecting blood vessels and organs, disability, and premature death. Research indicates that depression can significantly raise the risk of developing T2D, potentially through lifestyle and biological factors. Additionally, our modern diet presents a challenge with the increasing consumption of ultra-processed foods (UPF), which have been linked to a higher risk of obesity, diabetes, and hypertension. In this webinar, Dr. Norbert Schmitz and Dr. Akankasha Sen will share the synergistic effects of depression and UPF consumption on T2D risk and the risk of developing diabetes-specific complications for those with type 2 diabetes. Using longitudinal data from the CARTaGENE cohort, Dr. Schmitz and colleagues demonstrate whether the combination of these factors exacerbates the likelihood of developing T2D beyond their individual effects and whether other mechanisms affect the association, like smoking, alcohol consumption, and physical activity. Additional Details and Registration: https://canpath.ca/2024/03/webinar-ultra-processed-food-consumption-depression-diabetes/

CanPath at #CCRC2023: Canada’s Largest Population Laboratory for Cancer Research

Posted on by pathwp

Dr. Philip Awadalla, Scientific Director of CanPath, and Patient Partner/Atlantic PATH participant, Pauline McIntyre, will chair a panel at the Canadian Cancer Research Conference, “CanPath: Canada’s Largest Population Laboratory for Cancer Research” on Monday, November 13th at 11:40 AST. Presenters include Dr. Dylan O’Sullivan, Dr. Samina Abidi, Dr. Sara Nejatinamini, and Dr. Vikki Ho. Dr. Dylan O’Sullivan is a Research Scientist at Alberta Health Services and an Adjunct Assistant Professor in the Cumming School of Medicine, Department of Community Health Sciences at the University of Calgary. His research interests include reducing the cancer burden across the full cancer control continuum (prevention, screening, and outcomes) with the use of existing methods and the development of novel data analytics. Dr. O’Sullivan will be presenting on the risk factors for early-onset colorectal cancer using CanPath data. Dr. Samina Abidi is an Associate Professor in the Department of Community Health and Epidemiology at the Faculty of Medicine at Dalhousie University and is cross appointed in the Faculty of Computer Science. Dr. Abidi has a unique skill set where she is a clinician with an expertise in health informatics. Her research interests include health knowledge integration, modelling and computerization, patient-centred care, chronic disease self-management and behaviour modification, clinical guidelines based clinical decision support and care planning, ambient assistant living, data visualizations, health IT evaluation. Dr. Abidi will be presenting on a digital health and artificial based public health platform for cancer risk prediction using data from Atlantic PATH.   Dr. Sara Nejatinamini is a Research Associate at Alberta’s Tomorrow Project. She received her PhD degree in Nutrition and Metabolism from the University of Alberta. Prior to joining the ATP, she undertook postdoctoral training at the University of Calgary with a focus on health inequities. Dr. Nejatinamini’s research interests include public health, nutrition and cancer. Her research focuses on the role of modifiable lifestyle factors on cancer and other chronic disease risk. She applies epidemiological and implementation science methods and principles in her research to identify factors to prevent cancer and other chronic diseases and inform health interventions. Dr. Nejatinamini will be presenting on changes in breast and cervical cancer screening during the COVID-19 pandemic using data from Alberta’s Tomorrow Project.  Dr. Vikki Ho is the co-Scientific Director of CARTaGENE and holds the Chair in Sex and Gender Sciences in Cancer Research from the Canadian Institutes of Health Research. She is an Assistant Professor in the Department of Social and Preventive Medicine in the School of Public Health (ESPUM) at the University of Montreal and a Researcher at the affiliated Hospital Research Centre (CRCHUM). Dr. Ho’s research interests focus on the intersection of environmental, lifestyle, occupational, and individual susceptibility factors in cancer etiology. Dr. Ho will be presenting on CARTaGENE’s research platform and the wide array of data sources for cancer prevention research, including environmental factors and biomarkers. She will specifically focus on occupational exposures and lung cancer biomarkers, and occupational exposures to endocrine disrupting chemicals and colorectal cancer risk. Dr. Ho will also present a poster on the CARTaGENE cohort. Posters will be up for the duration of the conference and during viewing sessions on Sunday, November 12th from 12-1:30pm AST and Monday, November 13th from 1:10-2:40pm AST. 

New Publication – Depression, Anxiety and Risk of Cancer

Posted on by pathwp

We are pleased to share that the first results from the Psychosocial Factors and Cancer Incidence (PSY-CA) consortium have been published in Cancer. Led from the Netherlands by Dr. Lonneke van Tuijl and Dr. Joost Dekker, this study includes 18 cohorts with more than 300,000 participants including Atlantic PATH, the Ontario Health Study and CARTaGENE from CanPath. Our local team members include Mr. Yunsong Cui (Atlantic PATH) who completed all local analyses, Dr. Ellen Sweeney (Atlantic PATH) and Dr. Melanie Keats (Dalhousie University). Depression and anxiety have long been hypothesized to be related to an increased cancer risk, but, to date, findings are inconclusive. Individual participant data meta-analyses were performed within the PSY-CA consortium to assess the associations between depression, anxiety, and the incidence of various cancer types (overall, breast, lung, prostate, colorectal, alcohol-related, and smoking-related cancers). Findings from the study indicate that depression and anxiety are not related to increased risk for most cancer outcomes, except for lung and smoking-related cancers. This study shows that key covariates are likely to explain the relationship between depression, anxiety, and lung and smoking-related cancers. Link to publication: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34853 Link to Neuroscience News article: https://neurosciencenews.com/depression-anxiety-cancer-23769/    

CSEB Conference Update

Posted on by pathwp

The CanPath team was well represented at the Canadian Society for Epidemiology & Biostatistics (CSEB) Conference in Halifax on June 26-28, 2023. We had representatives from the CanPath National Coordinating Centre, Atlantic PATH, CARTaGENE, the Manitoba Tomorrow Project, and the Ontario Health Study that showcased the groundbreaking research and resources available related to epidemiology and biostatistics within CanPath and the regional cohorts. Throughout the conference, CanPath and the regional cohorts were well-represented in various sessions and discussions, particularly regarding data linkage. Some notable presentations included: ? Dr. Robin Urquhart, Scientific Director of Atlantic PATH, co-presented a workshop on data repositories in Canada ? Dr. Ellen Sweeney, Research Director of Atlantic PATH, presented at a concurrent session about research at Atlantic PATH exploring environmental exposure to arsenic and cancer risk using toxicological and machine-learning methods ? Dr. Vikki Ho, co-Scientific Director of CARTaGENE, co-presented a workshop on mentorship for junior faculty and funding opportunities ? Nicholas Cheng, PhD candidate at the Ontario Institute for Cancer Research, presented at a concurrent session about his research on leveraging population health cohorts to identify cancer biomarkers in blood up to seven years before diagnosis ? Poster sessions featured CanPath, the Manitoba Tomorrow Project, the Ontario Health Study, CARTaGENE, and more, showcasing the exceptional research happening at the regional level and how they can support epidemiological and biostatistical projects. Please connect with us to learn more about these projects. We are proud to contribute to advancing this critical field and look forward to continuing our efforts to drive positive health outcomes for all.                                   #CSEBConference2023 #Epidemiology #Biostatistics #EveryoneCounts #HealthResearch #Cohort #PopulationHealth

CanPath Representation at the Canadian Society for Epidemiology and Biostatistics Conference

Posted on by pathwp

We’re so glad to have representation from Atlantic PATH, CARTaGENE, Manitoba Tomorrow Project, Ontario Health Study, and CanPath at the Canadian Society for Epidemiology and Biostatistics Conference in Halifax this week! CanPath and the regional cohorts are well represented in the following sessions: Monday, June 26, 2023 Workshop 1 – Mentorship for Junior Faculty and Funding Opportunities: How to Break into the Game as a Junior Faculty Member [Dr. Vikki Ho, Scientific Co-Director, CARTaGENE] Workshop 3 – Data Repositories in Canada: Overview and Data Access 101  [Dr. Robin Urquhart, Scientific Director, Atlantic PATH] Tuesday, June 27, 2023 Concurrent Sessions B5: Lifecourse and Chronic Disease Epidemiology – Leveraging population health cohorts to identify cancer biomarkers in blood up to seven years prior to diagnosis          Presenter: Nicholas Chang, PhD candidate, OICR Poster Session   The Impact of Alcohol Consumption and Single Nucleode Polymorphisms on the High Rates of Colorectal Cancer in Atlantic Canada                                                                   Presenter: Carlee Feinstein, Research Assistant, St. FX                                                                                                                                                                                                        Authors: Carlee A Feinstein, Derrick G Lee, Allison Walsh, Tiffany S Bondo           The Manitoba Tomorrow Project: A Canadian Cohort Presented by: Dr. Travis Hrubeniuk, Project Lead, Manitoba Tomorrow Project Authors: Travis Hrubeniuk, Sachin Katyal, Donna Turner Canadian Partnership for Tomorrow’s Health (CanPath): Celebrang Compleng the Provincial Map and Cross-Province Data Linkage Presented by: Dr. John McLaughlin, Executive Director, CanPath Authors: John McLaughlin, Riaz Alvi, Philip Awadalla, Parveen Bhatti, Trevor Dummer, Jason Hicks, Vikki Ho, Grace Shen-Tu, Kimberly Skead, Ellen Sweeney, Donna Turner, Robin Urquhart, Jennifer Vena Examining the impact of inflammatory bowel disease on colorectal cancer risk in Atlantic Canada Presented by: Livia Clarke, Research Assistant, Dalhousie Medical School / St. FX Authors: Livia Clarke, Derrick Lee, Ellen Sweeney The Impact of Abnormal Sleep and Circadian Disruption on Atlantic Canada’s High Rate of Colorectal Cancer Presented by: Alison Walsh, Research Assistant, St. FX Authors: Alison J Walsh, Carlee A Feinstein, Tiffany S Bondoc, Megan K MacGillivray, Derrick G Lee The Ontario Health Study (OHS) Presented by: Sarah Salih, Data Analyst, Ontario Health Study Authors: Victoria Kirsh, Kimberly Skead, Kelly McDonald, Nancy Kreiger, Julian Lile, Karen Menard, John McLaughlin, Sutapa Mukherjee, Lyle Palmer, Vivek Goel, Mark Purdue, Sarah Salih, Philip Awadalla Smoking, aberrant DNA methylaon of the F2RL3 and AHRR genes, and lung cancer risk                                                                                                                                                     Presented by: Vikki Ho, Scientific Co-Director, CARTaGENE                                                                                                                                                                                                         Authors: Alice Nguyen, Anita Koushiki, Laura Pelland-St. Pierre, Michael Pham, Romain Pasquet, Sherryl Tauylor, Delphine Bosson-Rieutort, Vikki Ho The influence of occupaonal risk factors on DNA methylaon in the AHRR and F2RL3 genes Presented by: Laura Pelland-St-Pierre Authors: Michael Pham, Laura Pelland-St-Pierre, Alice Nguyen, Romain Pasquet, Sherryl Taylor, Delphine Bosson-Rieutort, Anita Koushik, Vikki Ho Wednesday, June 28, 2023 Concurrent Session C5: Cancer Epidemiology II – Exploring Environmental Exposure to Arsenic and Cancer Risk in the Atlantic PATH Cohort using Toxicological and Machine Learning Methods Presenter: Dr. Ellen Sweeney, Research Director, Atlantic PATH Please feel free to contact Atlantic PATH, CanPath or any of the regional cohorts to learn more about these projects!

Most CanPath study participants had infection-acquired antibodies but few suspected COVID-19

Posted on by pathwp

Dr. Victoria Kirsh presented at a CanPath webinar this week to present results from the SUPPORT-Canada study, funded by the federal COVID-19 Immunity Task Force (CITF). Data and blood spot samples were used from 22,300 participants from Atlantic PATH, CARTaGENE, the Ontario Health Study, Manitoba Tomorrow Project, Alberta’s Tomorrow Project, and BC Generations. Key findings include: 62% of participants had a COVID-19 infection based on anti-N measured antibody levels. Among those, 86% did not suspect they had ever had COVID-19. 95% of the COVID-19 infections were observed during the Omicron period. Risk of infection was increased among younger individuals, males, essential workers, and those who travelled. Participants with a reported COVID-19 infection reported symptoms from mild to severe, but few required hospitalization. The effectiveness of full or booster vaccination in preventing COVID-19 Omicron infection is short-term, only lasting 4 months. Time since last dose is a more important determinant of protection against infection than the number of doses. Antibody levels are correlates of vaccine-induced protection. Prior COVID-19 infection protects against reinfection for 8 months. The CanPath SUPPORT-Canada study has provided important findings related to the COVID-19 pandemic, vaccines and infections. With only 4 months of protection, these findings suggest that booster campaigns could be strategically used to rapidly boost immunity before upcoming waves of infection. Further, the longitudinal nature of CanPath participants ensures that we have a nationally representative population that can be followed for years to come (e.g., impact of Long COVID, future vaccinations, etc.). Link to recorded webinar: To come Link to webinar slide deck: https://www.covid19immunitytaskforce.ca/wp-content/uploads/2023/05/canpath-webinar-may-2023.pdf Link to CITF’s post: https://www.covid19immunitytaskforce.ca/most-canpath-study-participants-had-infection-acquired-antibodies-but-few-suspected-covid-19/